Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier
Abstract
Nanotechnology involves the design, synthesis, and characterization of materials and devices that have a functional organization in at least one dimension on the nanometer (ie, one billionth of a meter) scale. One area in which nanotechnology may have a significant clinical impact in neuroscience is the selective transport and delivery of drugs and other small molecules across the blood brain barrier that cannot cross otherwise. Using a variety of nanoparticles composed of different chemical compositions, different groups are exploring proof-of-concept approaches for the delivery of different antineoplastic drugs, oligonucleotides, genes, and magnetic resonance imaging contrast agents. This review discusses some of the main technical challenges associated with the development of nanotechnologies for delivery across the blood brain barrier and summarizes ongoing work.
Abbreviations: AFM, atomic force microscopy, BBB, blood-brain barrier, CNS, central nervous system, EAE, experimental autoimmune encephalomyelitis, HAT, African trypanosomiasis, MRI, magnetic resonance imaging, NMDA, N-methyl-d-aspartate, PEG, polyethylene glycol, PLGA, poly(lactic-co-glycolic acid), TH, tyrosine hydroxylase
Keywords: Nanotechnology, CNS, Bioengineering, Blood-brain barrier, Drug delivery
To access this article, please choose from the options below
PII: S0090-3019(06)00696-3
doi:10.1016/j.surneu.2006.08.033
© 2007 Elsevier Inc. All rights reserved.
